Carmine Therapeutics
Cambridge, United States· Est.
Non‑viral gene therapy platform using red blood cell vesicles to deliver scalable genetic medicines.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Non‑viral gene therapy platform using red blood cell vesicles to deliver scalable genetic medicines.
OncologyRare Genetic DiseasesHematology
Technology Platform
REGENT™ platform delivers nucleic‑acid therapeutics via red blood cell extracellular vesicles, offering non‑viral, high‑capacity, and low‑immunogenicity gene delivery.
Opportunities
Scalable, non‑viral gene delivery could capture market share in gene‑therapy indications where viral vectors face safety or capacity constraints.
Risk Factors
Regulatory approval pathways for extracellular vesicle therapeutics are still emerging, and manufacturing scale‑up may encounter technical challenges.
Competitive Landscape
Carmine competes with other non‑viral platforms (e.g., Codiak, Arrowhead) and viral vector leaders; its RBCEV approach offers distinct immunogenicity and payload advantages.